Company News: MediGene Signs Commercialization Agreement for Veregen / ProBioGen Is Granted New Divisional Patent on Duck Cell Line
MediGene AG has signed a license and supply agreement with Meditrina Pharmaceuticals for the supply and commercialization of Veregen® in Greece and Cyprus. Meditrina will promote and distribute Veregen® for the treatment of genital warts in both territories. Upon the achievement of specific milestones, MediGene will be entitled to successive payments totaling up to 900 thousand euros, and will receive the first milestone payment upon the initiation of the approval procedure in Greece. In addition, MediGene will supply Meditrina with finished product and will receive double-digit royalties on net sales. MediGene believes that Greece is the sixth largest potential European market for Veregen® sales volume.
MediGene has already entered into marketing partnerships for Veregen® with Nycomed, Inc. for the USA, Solvay (acquired by Abbott on February 15, 2010) for Germany, Austria and Switzerland, Juste S.A.Q.F for Spain and Portugal and Teva Pharmaceuticals Industries Ltd. for Israel. For further information, please click here.
Also today, ProBioGen has announced that it has been granted a divisional patent on its prorietary AGE1 cell line.
The patent covers the production of Modified Vaccinia Ankara (MVA) in duck cell lines. As these cells are free from endogenous particle-associated retrovirus activity, they are superior to current production substrates derived from chicken. The discovery has wide implications for the industrial production of one of the most promising recombinant vaccine vectors against infectious disease challenges such as HIV and malaria. Read more here.